Identifying what we have learned when implementing risk-based monitoring
|
|
- Arabella Sparks
- 5 years ago
- Views:
Transcription
1 Identifying what we have learned when implementing risk-based monitoring Outsourcing in Clinical Trials - West Coast 2017 Neil Vivian Senior Director of Business Solutions February, 2017 The EDC of choice for over 5,000 clinical trials around the world
2 Program Agenda Guidance for risk-based monitoring a recap Dynamically selecting data for SDV overview of functionality Some statistics from production trials Unpicking the rationale and process in remote monitoring Sponsor experience and observations 2
3 Program Agenda Guidance for risk-based monitoring a recap Dynamically selecting data for SDV overview of functionality Some statistics from production trials Unpicking the rationale and process in remote monitoring Sponsor experience and observations 3
4 Recap of Guidance FDA believes that risk-based monitoring could improve sponsor oversight of clinical investigations. Risk-based monitoring, including the appropriate use of centralized monitoring can meet statutory and regulatory requirements. There may be minimal benefit in comparing 100% of the source data for each subject to the CRFs for each study visit. Rather, it may be sufficient to compare the most critical data points for a sample of subjects and study visits as an indicator of data accuracy. Verify critical source data remotely in cases where such source data are accessible. 4
5 And the Survey says? BVMA Survey Overview Results of a survey that the BVMA (German Federation of CROs) initiated among the member companies of the EURCROF (the European Federation of CROs) following a Workshop on RBM. 180 respondents completed questionnaires between August 2014 and January all were analyzable Distribution across CROs - Large (71), Mid-Size (47), Small (48), Other (14) OmniComm is a member of the BVMA with active participation in their RBM working group. 5
6 Selected Survey Results 6
7 What is SDV s I pa t o Data Qualit? SDV Has Minimal Impact on Site-Entered Data 3.7% DATA THAT IS EVER CORRECTED 1.1% All Site-Entered Data Impacted By SDV Source: DIA Journal, Therapeutic Innovation & Regulatory Science, November
8 SDV More Rele a t for AE Reporti g 15% 11,8% 12% 9% 7,5% <= 1 day <= 7 days 6% 3,6% 3% 1,7% 0% AE SAE Source: DIA Journal, Therapeutic Innovation & Regulatory Science, November 2014 ~7% to 12% of AEs Entered Following SDV 8
9 Program Agenda Guidance for risk-based monitoring a recap Dynamically selecting data for SDV overview of functionality Some statistics from production trials Unpicking the rationale and process in remote monitoring Sponsor experience and observations 9
10 Selecting data for SDV The guidance allows <100% SDV as part of a risk-based monitoring plan Should take into account Site Risk Rating Criticality of Data (e.g., Safety, Primary Endpoint) Triggers to change Monitoring Level (e.g., Serious Adverse Event) Balance of on-site and central monitoring Should be automatically managed in EDC If the system picks the data to SDV, it is more defensible than if people pick the data to SDV 10
11 System Functionality Sites Risk Rating Randomize Patients Monitoring Level All Forms None Critical All Critical All Critical All Critical 11
12 Notes on System Functionality Mo itori g Le el i itiall set usi g a stratified, lo k-based randomization Mo itori g Le el is a piece of clinical data May be hidden using standard security techniques May be the target of an edit check E.g., If patie t e perie es a SAE, ha ge alue to All If manually updated, requires a reason for change Only selected forms need to be monitored, others can be signed when complete (no open queries) 12
13 Additional DM Reports to Track Monitor Activity 13
14 Program Agenda Guidance for risk-based monitoring a recap Dynamically selecting data for SDV overview of functionality Some statistics from production trials Unpicking the rationale and process in remote monitoring Sponsor experience and observations 14
15 Statistics (1) Item Number of Production Trials analyzed Number of Patients in each Trial Number of Monitoring Levels Average duration to date Value (except one with 20) ~1 year 15
16 Statistics (2) Risk Ratings For 11 of the 12 trials, either there is no site risk rating or the risk ratings are initially the same for all sites For one trial there is a distribution of sites across four risk ratings 16
17 Statistics (3) SDV Coverage Trial # Patients % Forms for SDV Trial A Trial B Trial C Trial D Trial E Trial F Trial G Trial H Trial I Trial J Trial K Trial L Weighted Average = 40% On average, an additional 5% of forms were monitored even though they didn t need to be 17
18 Setting Monitoring Level Many trials set first two patients at each site to 100% SDV Many trials have different monitoring level selections for Screen Failures Example reasons for changing the monitoring level: SAE for the patient Early termination Device implant performed Dose escalation 18
19 Summary of Risk-Based Monitoring Statistics Risk-Based Monitoring is now in mainstream, production use If ou re still o deri g a out it, ou re ehi d our peers The same techniques used for treatment randomization may be used for randomizing the monitoring levels Standard practice is to set all site risk ratings the same Can modify over time based on experience Target SDV coverage is around 40-50% 19
20 Program Agenda Guidance for risk-based monitoring a recap Dynamically selecting data for SDV overview of functionality Some statistics from production trials Unpicking the rationale and process in remote monitoring Sponsor experience and observations 20
21 A little digression how do you submit expenses? 21
22 Scan the paper document 22
23 Attach to the expense record 23
24 If it orks for e pe se reporti g Wh a t e do the same for clinical data? You re ad! It s a iolatio of patient privacy The sites o t do it The sites do t have scanners 24
25 Example Informed Consent Form Patient name and Signature blacked out Date and Investigator information can be monitored remotely 25
26 Entry and Scanning Process 1 Scan 3 Attach PDF to CRF Confirm redaction 2 Enter data into EDC DEMOG DEMOG Demog IC DEMOG Informed Consent 4 Monitor centrally I/E 26
27 Program Agenda Guidance for risk-based monitoring a recap Dynamically selecting data for SDV overview of functionality Some statistics from production trials Unpicking the rationale and process in remote monitoring Sponsor experience and observations 27
28 Informed Consent Implementation - Statistics Item Study Phase Number of sites Number of patients Number of Informed Consent Versions Study duration to date Value IV ~ 2 years 28
29 Observations from the Sponsor I the egi i g the sites fou d it hard, ut it e a e eas after a fe ti es. It feels like atta hi g do u e ts to a e ail. It akes it er eas for the o itors to he k all poi ts fro e ept for the patie t s sig ature a d a e. the ICF The i e thi g here is that e a alread sig al issues ith the ICF efore e e er go ph si all to the site. Most sites e isit earl. Duri g o itori g e e er fou d the o plete ICF issi g. 29
30 Summary Attaching redacted source documents to the clinical data can significantly aid a o itor s ork Sites can be motivated to participate It s ot i possi le! 30
31 31
The GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationTargeted technology and data management solutions for observational studies
Targeted technology and data management solutions for observational studies August 18th 2016 Zia Haque Arshad Mohammed Copyright 2016 Quintiles Your Presenters Zia Haque Senior Director of Data Management,
More informationInitially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees
Location: Los Angeles Research Institute: Los Angeles, CA Investigation Product/Test Article: Laftr Visit Mechanism: On-site Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationConducting Monitoring Visits for Investigator-Initiated Trials (IITs)
Conducting Monitoring Visits for Investigator-Initiated Trials (IITs) Clinical Research Coordinator Society (CRCS) Forum 25 July 2014 Xia Yu Clinical Research Associate Singapore Clinical Research Institute
More informationAN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES
1 AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES Key Clinical Study Tasks and Activities 2 Discussion of Key Tasks and Activities 3 Development of the Clinical Protocol and Study Materials 3 Qualification
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
More informationSite-Less CRO Model and esource: Framework for Action
Site-Less CRO Model and esource: Framework for Action Joe Martinez, RPh, PDE, PPC Princeton, NJ In-home and site-less clinical trials: changing the landscape How to test drugs, devices and procedures better
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationSelf-Monitoring Tool
This form is designed for research personnel to use to assess their compliance with TTUHSC El Paso IRB policies and procedures, and federal regulations and guidance governing research with human subjects,
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationSARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY
PS1006 SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY TITLE: Satellite Site Management Plan Job Title of Reviewer: POLICY #: EFFECTIVE DATE: REVISED DATE: POLICY TYPE: Elizabeth Carr, R.N.,
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More informationComprehensive Protocol Feasibility Questionnaire
Protocol Title: Potential Principal Investigator: Regulatory Coordinators: Department Chair: PROJECT FEASIBILITY PI and Study Team: YOUR RESPONSES TO THIS SURVEY CONSTITUTE A BEST ESTIMATE OF RESOURCES
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationGood Documentation Practices. Human Subject Research. for
Good Documentation Practices for Human Subject Research Bridget M. Psicihulis, RHIA, CCRC Quality Improvement Unit Coordinator Human Research Protection Program Wheaton Franciscan Healthcare (last updated
More informationAudits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
More informationOverview ICH GCP E6(R2) Integrated Addendum
2017 Biomedical Research Alliance of New York LLC CITI Program is a division of BRANY Overview ICH GCP E6(R2) Integrated Addendum Introduction On 15 December 2016, the International Council for Harmonistion
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationUNC Lineberger Comprehensive Cancer Center. Data and Safety Monitoring Plan
UNC Lineberger Comprehensive Cancer Center Data and Safety Monitoring Plan Norman E. Sharpless, MD, Director P30CA-16086 Approved: September 29, 2014 Table of Contents Monitoring Progress of Trials and
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationRequest for Proposal
Request for Proposal Electronic Data capture and Data Management activities to support the conduction of a phase 2 trial in Chagas Disease Dated: 29 June 2015 Page 1 TABLE OF CONTENTS 1. PURPOSE... 3 2.
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationAnnex VIIIA Guideline for correct preparation of a model patient information sheet and informed consent form (PIS/ICF)
DEPARTMENT OF MEDICINAL PRODUCTS FOR HUMAN USE Annex VIIIA Guideline for correct preparation of a model patient information sheet and informed consent form (PIS/ICF) Version 10 th November 2016 Date of
More informationIMPROVING YOUR CLINICAL TRIAL & ENHANCING THE PATIENT EXPERIENCE
ebook IMPROVING YOUR CLINICAL TRIAL & ENHANCING THE PATIENT EXPERIENCE Applying a patient-centered approach to enhance clinical trial performance, improve data quality, and ensure safety and efficacy.
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting
Study Management SM 306.00 STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick M. Schnell, MD,
More information4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.
SOP #: MON-101 Page: 1 of 6 1. POLICY STATEMENT: The DF/HCC understands that external sponsors are required to monitor the progress of clinical investigations and ensure appropriate research data collection
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationGood Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More information36 th Annual Meeting Preconference Workshop P4 Handout
36 th Annual Meeting Preconference Workshop P4 Handout Clinical Trial Management in Multicenter Trials: Collaborating for Success Meet Our Team Dixie Ecklund, RN, MSN, MBA Associate Director, University
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationThis is a full time post offered on a fixed-term basis until 31 August 2019.
Faculty of Medicine and Health Sciences Norwich Medical School CTU Trial Assistant REF: SC3019 This is a full time post offered on a fixed-term basis until 31 August 2019. The Post A Clinical Trial Assistant
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More informationRisk-Benefit Ratio and Determinations. Sarah Mumford, Ammon Pate, Annie Risenmay IRB Operations Managers University of Utah
Risk-Benefit Ratio and Determinations Sarah Mumford, Ammon Pate, Annie Risenmay IRB Operations Managers University of Utah Risk-Benefit Ratio and Determinations Nuances of Risk Determinations Direct Benefit
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationGood Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center
Good Clinical Practice Lisa de Blieck MPA CCRC Clinical Trials Coordination Center Good Clinical Practice (GCP) An international standard for the design, conduct, performance, monitoring, auditing, recording,
More informationFDA Inspection Readiness
FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection
More informationCourse program. Good Clinical Practice (GCP) course for surgeons
Course program Good Clinical Practice (GCP) course for surgeons 2 Good Clinical Practice (GCP) course for surgeons 7 Principles of Education Based on needs Relevant Interactive Leads to verifiable outcomes
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-D
Page 1 of 8 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Data Safety and Monitoring Committee Administrative and Revision: N/A Revision Date: N/A Functional
More informationIN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD
COMPLIANCE WITH ISO 14155:2011 GUIDANCE FOR ENSURING YOUR CLINICAL STUDY IS BEING DESIGNED, EXECUTED, AND MONITORED IN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD Introduction: An increasing trend
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationQUALITY ASSURANCE PROGRAM
QUALITY ASSURANCE PROGRAM Elaine Armstrong, MS Quality Assurance Manager PURPOSE Verify accuracy of submitted data Verify compliance with protocol and regulatory requirements Provide educational support
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationWARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Charles J. Coté, M.D. Ref: 09-HFD-45-02-04
More informationRoles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS
Nursing Chapter 610-X-5 ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS 610-X-5-.01 610-X-5-.02 610-X-5-.03 610-X-5-.04 610-X-5-.05
More informationHertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust
Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust STANDARD OPERATING PROCEDURE FOR RESEARCH Definition of Responsibilities for Externally
More informationClinical Data Transparency CLINICAL STUDY REPORTS APPROACH TO PROTECTION OF PERSONAL DATA
Clinical Data Transparency CLINICAL STUDY REPORTS APPROACH TO PROTECTION OF PERSONAL DATA CLINICAL STUDY REPORTS APPROACH TO PROTECTION OF PERSONAL DATA Background TransCelerate BioPharma Inc. is a non-profit
More informationSite Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG
Site Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG INFORMATION AND GUIDANCE SHEET FOR THE COMPLETION OF THE SITE SIGNATURE AND
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL SECTION 21 APPLICATION FORM Only to be used for orthodox/allopathic medicines for human use. 1. Fax completed form (i.e. pages 1-10), proof of payment of application fee (if applicable)
More informationRegulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies
Regulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies DIRECTIONS: 1. The purpose of a regulatory binder is to assure that all essential elements are maintained in an organized
More informationPablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN
Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 9 PARTNER PREGNANCY FOLLOW UP CONSENT FORM Sponsor / Study Title: Protocol Number: Principal Investigator: (Study Doctor) Gilead Sciences,
More informationResearch Compliance Oversight in the Department of Veterans Affairs
Research Compliance Oversight in the Department of Veterans Affairs Karen M. Smith, PhD Director, Midwestern Regional Office Office of Research Oversight Department of Veterans Affairs Health Care Compliance
More informationOverview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.
Overview of the IMB s Approach to Inspection of Good Clinical Practice GCP Seminar Dublin, 27 th January 2010 Deirdre O Regan GCP/Pharmacovigilance Inspection Manager Slide 1 Introductions/Organisation
More information12.0 Investigator Responsibilities
12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement, the investigational
More informationTraining, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan
Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan Cynthia F. Kleppinger, M.D. Senior Medical Officer Office of Scientific Investigations Office
More informationU S I N G C T O a t U H N f o r M u l t i - S i t e R e s e a r c h
U S I N G C T O a t U H N f o r M u l t i - S i t e R e s e a r c h How to get ethics approval through CTO for multi-site studies and how to obtain and maintain IA at UHN Today s Agenda 1. What is a Research
More informationPLATELET-ORIENTED INHIBITION ISCHEMIC STROKE (POINT) MONITORING PLAN IN NEW TIA AND MINOR. Version 2.0 Updated 11 May 2017
PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) MONITORING PLAN Version 2.0 Updated 11 May 2017 Monitoring Plan Table of Contents 1.0 Introduction... 4 2.0 Purpose... 4 3.0 Review
More informationCLOSE OUT VISIT REPORT (NO CRF TO MONITOR)
Date: Page: 1 of 8 CLOSE OUT VISIT REPORT (NO CRF TO MONITOR) Protocol: PI Name: PI Address: Date of Visit: Monitor(s): Other Sponsor Personnel Present: Site Personnel Present at Visit (include names and
More informationPROMPTLY REPORTABLE EVENTS
PROMPTLY REPORTABLE EVENTS PURPOSE AND SCOPE To define the structure and responsibility for reporting unanticipated problems that occurs during the conduct of research. APPLICABLE REGULATIONS Policy II.02
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationCOATS Coordinating Center Memo #3
TO: COATS Study Coordinators FROM: Kimberly Ring Data Coordinating Center DATE: March 25, 2009 RE: SAE QxQ COATS Coordinating Center Memo #3 This memo addresses the COATS SAE QxQ, which is now available.
More informationAbstract submission regulations and instructions
Abstract submission regulations and instructions Regular abstract submission deadline 26 September 2018, 21:00hrs CEST (CEST = Central European Summer Time / Local Swiss time) Late-breaking abstract deadline
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationAgenda Item 6.7. Future PROGRAM. Proposed QA Program Models
Agenda Item 6.7 Proposed Program Models Background...3 Summary of Council s feedback - June 2017 meeting:... 3 Objectives and overview of this report... 5 Methodology... 5 Questions for Council... 6 Model
More informationFDA Medical Device Regulations vs. ISO 14155
Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50
More informationRecord or Document Type Retention Period Relevant Legal Citation(s) IRB Records: Training Records;
TEXAS HEALTH RESOUCES Table 17-III. Record Retention Schedule Human Subject Research Records and Documents Approved by THR System Performance Council (SPC): 19 January 2010 Effective Date: October 14,
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationA Million Little Pieces: Developing a Controlled Substance Diversion Program. Tanya Y. Barnhart, PharmD, BCPS
A Million Little Pieces: Developing a Controlled Substance Diversion Program Tanya Y. Barnhart, PharmD, BCPS I have no conflicts of interest to disclose Objectives Explain the importance of building a
More informationPage 2- Alan Rapoport, M.D.
~ I^ 1 ) ~~ ~~ ls sr~ L DEPA RTMENT OF HEALTH & HUMAN SERViCES Public Health Se rvice J~T~ ;awyicf,{,~-
More informationCLIC Clinical Investigator (And Site Staff) Certification
CLIC Clinical Investigator (And Site Staff) Certification CLIC Level 1: 23-24 March 2015 CLIC Level 2: 25-27 March 2015 Cape Town (Venue to be confirmed) C PD points L e v e l 1 : 1 4 G e n e r a l, 2
More informationAddendum to ICH E6 (R2)
Addendum to ICH E6 (R2) Stephanie Shapley (US FDA) - Rapporteur Dr. Fergus Sweeney (EMA) - Regulatory Chair Date: December 15, 2015 International Council for Harmonisation of Technical Requirements for
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More information16 STUDY OVERSIGHT Clinical Quality Management Plans
16 STUDY OVERSIGHT... 1 16.1 Clinical Quality Management Plans... 1 16.2 Site Visits by the LOC, SDMC and LC... 2 16.3 Protocol Team Oversight... 3 16.4 Oversight of Reportable Protocol Deviations... 3
More informationPrepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department
AUDIT MANUAL Prepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department Original: October 2001 Revised: June 2010 American College of Radiology
More informationRetrospective Chart Review Studies
Retrospective Chart Review Studies Designed to fulfill requirements for real-world evidence Retrospective chart review studies are often needed in the absence of suitable healthcare databases and/or other
More informationInvitation to join the Europea Net ork for the Economic Cohesion and Solidarity in ural areas EN u e under the Program Europe for Citizens
Invitation to join the Europea Net ork for the Economic Cohesion and Solidarity in ural areas EN u e under the Program Europe for Citizens We are looking for: - towns, municipalities or their twinning
More information1. Introduction, purpose of this Standard Operating Procedure (SOP)
Details Document Type Document name Ref # Version Effective from Review date Owner Prepared by Reviewed by Approved by Superseded documents Relevant regulations/legislation/guidelines/reference Standard
More informationStandard Operating Procedure
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-07-004 Recording, managing and reporting Adverse Events for Clinical Trials of Investigational Medicinal Products and trials of Advanced
More informationPractice Tools for Safe Drug Therapy
Practice Tools for Safe Drug Therapy Practice Tools for Safe Drug Therapy Pharmacists and pharmacy technicians make sure the right person gets the right dose of the right drug at the right time and takes
More informationSection 14. Study Reporting Plan
Section 14. Study Reporting Plan 14.1 Purpose of Reporting Plan... 1 14.2 Study Reports... 1 Table 14-1: MTN-027 SDMC Reports Distributed via Email... 2 Table 14-2: MTN-027 SDMC Reports Posted on Atlas...
More informationLOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP)
LOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP) Effective Date: February 7, 2013 SOP Title: Study Monitoring Visits - Process for Access
More informationSOP : Quality Assurance Inspections SCOPE RESPONSIBILITIES. APPROVAL AUTHORITY EFFECTIVE DATE May PURPOSE 2.
TITLE SCOPE RESPONSIBILITIES APPROVAL AUTHORITY EFFECTIVE DATE May 2018 901: Quality Assurance Inspections All research submitted to the University of British Columbia s Research Ethics Boards The Vice
More informationOffice of Clinical Research. CTMS Reference Guide Patient Entry & Visit Tracking
Se Office of Clinical Research CTMS Reference Guide Patient Entry & Visit Tracking Table of Contents Logging into CTMS... 3 Search and Recruitment / Quick Search... 4 How to Configure Quick Search Fields...
More informationClinical Trial Quality Assurance Common Findings
Clinical Trial Quality Assurance Common Findings Objectives Identify common findings found in research study reviews conducted by the CTQA Program Understand what findings require an action plan vs. a
More informationCDISC Standards Webinar Latest Updates and Additions 31 Jan 2013
CDISC Standards Webinar Latest Updates and Additions 31 Jan 2013 CDASH-SAE Domains CDISC CDASH SAE Team Update Rhonda Facile, CDISC Gary Walker, Quintiles CDISC 2013 2 Agenda Background Mapping CDASH to
More informationResearch Adverse Event and Safety Reporting Procedures Outcome Statement: Title:
Title: Research Adverse Event and Safety Reporting Procedures Outcome Statement: Research Teams will be able to correctly identify and report Adverse Events and complete Annual Safety Reports for research
More informationFEDERAL DEPARTMENTS AND AGENCIES WITH DIRECT INVOLVEMENT IN CT SCANNING
Appendix VI FEDERAL DEPARTMENTS AND AGENCIES WITH DIRECT INVOLVEMENT IN CT SCANNING Various aspects of CT scanning come under the jurisdiction of different Federal departments and agencies. Many of these
More informationIntroduction to the United States Food and Drug Administration (FDA) and FDA Inspection Process VOICE
Introduction to the United States Food and Drug Administration (FDA) and FDA Inspection Process VOICE 2011 MTN Annual Meeting March 27, 2011 Lisa Noguchi, MSN Donna Germuga, DAIDS, OCSO, RN, BSN Objectives
More informationONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, N.J November 28,2011
ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, N.J. 08933 November 28,2011 Division of Dockets Management (HFA-305) U.S. Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket
More informationERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants
Share. Care. Cure. ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants An initiative of the Version 1.1 April 2016 1 History of changes Version Date Change Page 1.0 16.03.2016 Initial
More informationTheradex Audit 2013: Findings & Corrective Action
Theradex Audit 2013: Findings & Corrective Action Overview Discuss Findings and CAP for: Informed Consent Content IRB Informed Consent Eligibility Treatment Serious Adverse Events Response General Data
More information